FOSCARNET

/static/temp/default.svg Search structure
Synonyms
Status
Molecule Category Free-form
ATC J05AD01
UNII 364P9RVW4X
EPA CompTox DTXSID0048478

Structure

InChI Key ZJAOAACCNHFJAH-UHFFFAOYSA-N
Smiles O=C(O)P(=O)(O)O
InChI
InChI=1S/CH3O5P/c2-1(3)7(4,5)6/h(H,2,3)(H2,4,5,6)

Physicochemical Descriptors

Property Name Value
Molecular Formula CH3O5P
Molecular Weight 126.0
AlogP -0.16
Hydrogen Bond Acceptor 2.0
Hydrogen Bond Donor 3.0
Number of Rotational Bond 1.0
Polar Surface Area 94.83
Molecular species ACID
Aromatic Rings 0.0
Heavy Atoms 7.0
Assay Description Organism Bioactivity Reference
Antiviral activity was determined against Human cytomegalovirus (HCMV) strain AD-169 using CPE inhibition assay Human herpesvirus 5 64.9 ug.mL-1
Antiviral activity was determined against Human cytomegalovirus (HCMV) strain Davis using CPE inhibition assay Human herpesvirus 5 38.7 ug.mL-1
Inhibitory activity against herpes simplex virus type-1 (HSV-1) replication in KB cells Human herpesvirus 1 189.0 ug.mL-1
In vitro inhibition of Na(+)-gradient-dependent uptake of 32 inorganic phosphate (Pi) by BBM vesicles freshly prepared from the rat renal cortex Rattus norvegicus -63.0 %
Inhibition of Varicella-Zoster virus DNA polymerase (95 uL) activity in a solution containing 6.4 mM HEPES (pH 7.5), incubation for 12 minutes at 26 degrees C; [nd = not determined] Human herpesvirus 3 280.0 nM
Inhibition of HIV1 reverse transcriptase at 20 ug/mL Human immunodeficiency virus 1 96.46 %
Inhibition of human DNA polymerase gamma Homo sapiens 280.0 nM
Inhibition of human DNA polymerase gamma by scintillation proximity assay Homo sapiens 280.0 nM
Inhibition of HIV reverse transcriptase assessed as incorporation of [3H]dTMP at 0.6 uM Human immunodeficiency virus 63.0 %
Inhibition of human polymerase gamma by scintillation proximity assay Homo sapiens 280.0 nM
Binding affinity to HIV1 reverse transcriptase p66/p51-polypurine tract primer complex in presence of Mg2+ ions by band shift assay Human immunodeficiency virus 1 400.0 nM
Antiviral activity against ganciclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Human herpesvirus 5 17.0 ug.mL-1
Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl cytosine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Human herpesvirus 5 14.0 ug.mL-1
Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl adenine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Human herpesvirus 5 35.0 ug.mL-1
Antiviral activity against foscarnet-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Human herpesvirus 5 135.0 ug.mL-1
Antiviral activity against acyclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Human herpesvirus 5 37.0 ug.mL-1
Antiviral activity against HCMV 6 with U97 mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity Human herpesvirus 5 34.0 ug.mL-1
Antiviral activity against HCMV 521 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity Human herpesvirus 5 29.0 ug.mL-1
Antiviral activity against HCMV 530 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity Human herpesvirus 5 31.0 ug.mL-1
Inhibition of wild type HIV1 reverse transcriptase M184V mutant assessed as inhibition of DNA primer extension using [8-3H(N)]-dATP by scintillation proximity assay Human immunodeficiency virus 1 800.0 nM
Inhibition of human NaPi2a expressed in HEK293 cells coexpressing tetracyclin assessed as reduction in uptake of 33P-radiolabeled Pi at 5 mM incubated for 20 to 30 mins prior to substrate addition Homo sapiens 84.0 %
Inhibition of HIV1 reverse transcriptase p66/p51 polymerase using PPT57 DNA/Cy5-labeled PPT24 as template/primer preincubated for 10 mins followed by dNTP addition measured after 5 mins by bromophenol blue staining based phosphor imaging analysis Human immunodeficiency virus 1 800.0 nM

Cross References

Resources Reference
ChEBI 127780
ChEMBL CHEMBL666
DrugBank DB00529
DrugCentral 1241
FDA SRS 364P9RVW4X
Human Metabolome Database HMDB0014670
Guide to Pharmacology 5497
KEGG C06456
PDB PPF
PharmGKB PA449706
PubChem 3415
SureChEMBL SCHEMBL23633
ZINC ZINC000008101109
CONTENTS